ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - ADC Therapeutics reported a quarterly loss of $0.56 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.74 per share a year ago [1] - The company's revenues for the quarter ended March 2024 were $18.05 million, missing the Zacks Consensus Estimate by 0.75% and down from $18.99 million year-over-year [1] - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [1] Stock Movement and Outlook - ADC Therapeutics shares have increased approximately 195.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.5% [2] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [2] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of $20.01 million, and for the current fiscal year, it is -$2.20 on revenues of $83.22 million [4] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - ThermoGenesis Holdings, Inc., another company in the same industry, is expected to report quarterly earnings of $0.01 per share, reflecting a year-over-year change of +100.3% [5]